Wells Fargo Maintains Equal-Weight on Amgen, Lowers Price Target to $275
Wells Fargo analyst Mohit Bansal maintains Amgen (NASDAQ:AMGN) with a Equal-Weight and lowers the price target from $285 to $275.
RBC Capital Maintains Sector Perform on Amgen, Lowers Price Target to $258
RBC Capital analyst Gregory Renza maintains Amgen (NASDAQ:AMGN) with a Sector Perform and lowers the price target from $268 to $258.
Amgen Records Slight Fall In Quarterly Earnings; Lower COVID-19 Manufacturing Pacts Impact Bottomline
Amgen Inc’s (NASDAQ:AMGN) fourth-quarter revenues were $6.84 billion, beating the consensus of $6.76 billion, largely unchanged from Q4 2021, and…
Earnings Scheduled For January 31, 2023
Companies Reporting Before The Bell
• Biophytis (NASDAQ:BPTS) is projected to report earnings for its first quarter.
Here’s How Much You Would Have Made Owning Amgen Stock In The Last 15 Years
Amgen (NASDAQ:AMGN) has outperformed the market over the past 15 years by 4.34% on an annualized basis producing…
Can Market Sustain Upward Momentum In Tech-Heavy Earnings Week? Apple, Amazon, AMD, Alphabet, Ford Among Key Quarterly Reports To Watch
With a full week of earnings behind us, it’s time to take stock of the fourth-quarter reporting season so far. Overall, the news flow has been mixed, although tech earnings have grossly disappointed.
Analyst Views Novo Nordisk’s Upcoming Obesity Drug Data To Lay Grounds For Eli Lilly’s Tirzepatide
Cantor Fitzgerald published around 40-page deep dive ahead of Novo Nordisk A/S's (NYSE: NVO) SELECT CV outcomes study, which is guided to complete in ~mid-2023.
Illumina Shares Tank After Annual Guidance Fall Short Of Expectations
During JP Morgan Conference, Illumina Inc (NASDAQ:ILMN) announced interim Q4 FY22 sales of $1.075 billion, lower than $1.10 billion in Q3 FY22.…
$100 Invested In Amgen 15 Years Ago Would Be Worth This Much Today
Amgen (NASDAQ:AMGN) has outperformed the market over the past 15 years by 5.15% on an annualized basis producing…